Predict your next investment

Pfizer company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
pfizer.com

See what CB Insights has to offer

Investments

37

Portfolio Exits

19

Funds

1

Partners & Customers

10

Service Providers

2

About Pfizer

Pfizer (NYSE: PFE) offers a diversified global health care portfolio including human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer products. Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge feared diseases. The company also collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

Pfizer Headquarter Location

235 East 42nd Street

New York, New York, 10017,

United States

212-733-2323

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pfizer

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Pfizer in 6 Expert Collections, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

P

Poop Tech

114 items

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

H

HLTH

92 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare

R

Rare Diseases

25 items

M

Microbiome

105 items

Pfizer Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Pfizer Rank

Latest Pfizer News

FDA authorizes booster dose of Pfizer’s COVID-19 vaccine for people 65 and older

Sep 23, 2021

DoD / Lisa Ferdinando / CC BY 2.0 The US Food and Drug Administration said Wednesday it would grant emergency use authorization for a booster dose of Pfizer's COVID-19 vaccine in people 65 and older, people at high risk of severe disease and people whose jobs put them at risk of infection. "After considering the totality of the available scientific evidence and the deliberations of our advisory committee of independent, external experts, the FDA amended the EUA for the Pfizer-BioNTech COVID-19 Vaccine to allow for a booster dose in certain populations such as health care workers, teachers and day care staff, grocery workers and those in homeless shelters or prisons, among others," acting FDA Commissioner Dr. Janet Woodcock  said in a statement. On Friday, vaccine advisers to the agency unanimously recommended emergency use authorization for a booster dose of Pfizer's vaccine for people 65 and older and those at risk of severe disease, to be six months after they get the first two doses. "The FDA considered the committee's input and conducted its own thorough review of the submitted data to reach today's decision," Dr. Peter Marks, who directs the FDA's vaccine arm, the Center for Biologics Evaluation and Research, said in a statement. "We will continue to analyze data submitted to the FDA pertaining to the use of booster doses of COVID-19 vaccines and we will make further decisions as appropriate based on the data." It was a consolation prize for Pfizer, which has asked for FDA approval to give its vaccine to everyone 16 and older six months after they are fully immunized with two shots. Pfizer had argued that it had enough evidence that immunity starts to wane after six months and that giving a booster restores the immunity safely. Vaccine advisers to the US Centers for Disease Control and Prevention have been discussing boosters, and will meet Thursday to act on the FDA's decision. The CDC must give its stamp of approval for any booster doses to be officially given. CDC's Advisory Committee on Immunization Practices can further tweak recommendations for how any vaccine booster doses should be given. In a letter sent Thursday and obtained by CNN, the CDC urged local and state health officials to wait to administer boosters until both agencies had signed off. Third doses are already approved for certain immunocompromised people, but not for the general public. About 2.3 million Americans have already received third doses of Pfizer's vaccine, according to the CDC. The-CNN-Wire

Pfizer Investments

37 Investments

Pfizer has made 37 investments. Their latest investment was in SicureMi as part of their Seed VC on September 9, 2021.

CBI Logo

Pfizer Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/22/2021

Seed VC

SicureMi

$0.43M

Yes

1

6/30/2021

Corporate Minority - P2P

Spero Therapeutics

$40M

Yes

1

2/17/2021

Series B - II

Imcyse

$25.63M

Yes

2

1/13/2021

Corporate Minority - P2P

Subscribe to see more

$99M

Subscribe to see more

10

1/12/2021

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/22/2021

6/30/2021

2/17/2021

1/13/2021

1/12/2021

Round

Seed VC

Corporate Minority - P2P

Series B - II

Corporate Minority - P2P

Corporate Minority

Company

SicureMi

Spero Therapeutics

Imcyse

Subscribe to see more

Subscribe to see more

Amount

$0.43M

$40M

$25.63M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

2

10

10

Pfizer Portfolio Exits

19 Portfolio Exits

Pfizer has 19 portfolio exits. Their latest portfolio exit was Cerevel Therapeutics on October 28, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/28/2020

Reverse Merger

$991

2

1/13/2020

Divestiture

$991

1

10/10/2019

IPO

$991

5

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

10/28/2020

1/13/2020

10/10/2019

00/00/0000

00/00/0000

Exit

Reverse Merger

Divestiture

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

1

5

10

10

Pfizer Acquisitions

47 Acquisitions

Pfizer acquired 47 companies. Their latest acquisition was Trillium Therapeutics on August 23, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/23/2021

Corporate Minority - P2P

$991

$26.5M

Acq - Pending

6

4/28/2021

Series C - II

$150.61M

Acquired

8

10/22/2020

Seed - II

$13M

Acquired

2

7/30/2019

IPO

Subscribe to see more

$991

$99M

Subscribe to see more

10

5/8/2019

Mezzanine

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

8/23/2021

4/28/2021

10/22/2020

7/30/2019

5/8/2019

Investment Stage

Corporate Minority - P2P

Series C - II

Seed - II

IPO

Mezzanine

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Total Funding

$26.5M

$150.61M

$13M

$99M

$99M

Note

Acq - Pending

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

6

8

2

10

10

Pfizer Fund History

1 Fund History

Pfizer has 1 fund, including Pfizer Breakthrough Growth Initiative.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/3/2020

Pfizer Breakthrough Growth Initiative

$500M

2

Closing Date

6/3/2020

Fund

Pfizer Breakthrough Growth Initiative

Fund Type

Status

Amount

$500M

Sources

2

Pfizer Partners & Customers

10 Partners and customers

Pfizer has 10 strategic partners and customers. Pfizer recently partnered with Fera Pharmaceuticals on August 8, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

8/12/2021

Licensee

Fera Pharmaceuticals

United States

Pfizer Shifts Glaucoma Drug to New Supplier Fera Pharmaceuticals

Pfizer said it chose Fera Pharmaceuticals because of its `` expertise and focus in ophthalmic medicines , '' and its `` understanding of the regulatory process '' for such drugs .

1

8/10/2021

Partner

IDEAYA Biosciences

United States

IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

IDEAYA Biosciences , Inc. and GlaxoSmithKline are collaborating on ongoing preclinical research , and GlaxoSmithKline will lead clinical development for the Werner Helicase program .

1

8/6/2021

Partner

GlaxoSmithKline

United Kingdom

More than 300 people will be laid off from Cumberland County plant beginning next month

That merger was completed in 2019 , with GlaxoSmithKline owning 68 percent of the new entity , and Pfizer owning 32 percent of the new joint venture .

1

7/23/2021

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/22/2021

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/12/2021

8/10/2021

8/6/2021

7/23/2021

7/22/2021

Type

Licensee

Partner

Partner

Licensor

Licensor

Business Partner

Fera Pharmaceuticals

IDEAYA Biosciences

GlaxoSmithKline

Country

United States

United States

United Kingdom

Subscribe to see more

Subscribe to see more

News Snippet

Pfizer Shifts Glaucoma Drug to New Supplier Fera Pharmaceuticals

Pfizer said it chose Fera Pharmaceuticals because of its `` expertise and focus in ophthalmic medicines , '' and its `` understanding of the regulatory process '' for such drugs .

IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

IDEAYA Biosciences , Inc. and GlaxoSmithKline are collaborating on ongoing preclinical research , and GlaxoSmithKline will lead clinical development for the Werner Helicase program .

More than 300 people will be laid off from Cumberland County plant beginning next month

That merger was completed in 2019 , with GlaxoSmithKline owning 68 percent of the new entity , and Pfizer owning 32 percent of the new joint venture .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Pfizer Service Providers

2 Service Providers

Pfizer has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P, Corporate Minority, and Acquired

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Acq - P2P, Corporate Minority, and Acquired

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Partnership data by VentureSource

Pfizer Team

117 Team Members

Pfizer has 117 team members, including current Chief Executive Officer, Albert Bourla.

Name

Work History

Title

Status

Albert Bourla

Chief Executive Officer

Current

Ian Read

Chief Executive Officer

Current

Christy A. Fleurat

President

Current

Dieter Weinand

President

Current

Brenda Cooperstone

Senior Vice President

Current

Name

Albert Bourla

Ian Read

Christy A. Fleurat

Dieter Weinand

Brenda Cooperstone

Work History

Title

Chief Executive Officer

Chief Executive Officer

President

President

Senior Vice President

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.